<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on November 19, 2021</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT04091880</url>
  </required_header>
  <id_info>
    <org_study_id>EV71-Flu-Combine-01</org_study_id>
    <nct_id>NCT04091880</nct_id>
  </id_info>
  <brief_title>Evaluation of the Safety and Immunogenicity of Simultaneously Administration of EV71 Vaccine and Influenza Vaccine</brief_title>
  <official_title>A Randomized, Controlled, Multicenter Phase 4 Clinic Trial to Evaluate the Safety and Immunogenicity of Simultaneously Administration of EV71 Vaccine and Influenza Vaccine (Split Virion),Inactivated</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>China National Biotec Group Company Limited</agency>
      <agency_class>Industry</agency_class>
    </lead_sponsor>
    <collaborator>
      <agency>Zhejiang Provincial Center for Disease Control and Prevention</agency>
      <agency_class>Other</agency_class>
    </collaborator>
    <collaborator>
      <agency>Henan Center for Disease Control and Prevention</agency>
      <agency_class>Other</agency_class>
    </collaborator>
    <collaborator>
      <agency>Guizhou Center for Disease Control and Prevention</agency>
      <agency_class>Other</agency_class>
    </collaborator>
    <collaborator>
      <agency>Wuhan Institute of Biological Products Co., Ltd</agency>
      <agency_class>Industry</agency_class>
    </collaborator>
    <collaborator>
      <agency>Changchun Institute of Biological Products Co., Ltd.</agency>
      <agency_class>Industry</agency_class>
    </collaborator>
    <collaborator>
      <agency>Peking University</agency>
      <agency_class>Other</agency_class>
    </collaborator>
    <collaborator>
      <agency>National Institutes for Food and Drug Control, China</agency>
      <agency_class>Other</agency_class>
    </collaborator>
  </sponsors>
  <source>China National Biotec Group Company Limited</source>
  <oversight_info>
    <has_dmc>Yes</has_dmc>
    <is_fda_regulated_drug>No</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
  </oversight_info>
  <brief_summary>
    <textblock>
      Subjects will be recruited and divided into 3 groups:&#xD;
&#xD;
        1. Experimental Group (378 subjects): combined immunization of EV71 vaccine and influenza&#xD;
           vaccine;&#xD;
&#xD;
        2. Control Group A (378 subjects): EV71 vaccine only;&#xD;
&#xD;
        3. Control Group B (378 subjects): influenza vaccine only;&#xD;
&#xD;
      All blood samples will be collected before and one month after vaccinatioin. The&#xD;
      immunogenicity and safety of both experimental and control groups will be compared and the&#xD;
      data be analyzed.&#xD;
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      To further evaluate the feasibility of simultaneously administration of EV71 vaccine and flu&#xD;
      vaccine, we design this clinical trial to test its immunogenicity and safety. 1134 subjects&#xD;
      aged from 6 to 11 months old are divided into one experimental group and two control groups&#xD;
      (control group A and B).&#xD;
&#xD;
      Each group includes 378 subjects and is divided again into 3 age-based subgroups: ① 6-7&#xD;
      months old; ② 8-9 months old; ③10-11 months old ; each subgroup has 126 subjects&#xD;
      respectively.&#xD;
&#xD;
      378 subjects from the experimental group will be simultaneously administrated with one dose&#xD;
      of EV71 vaccine (0.5 ml) and one dose of influenza vaccine (0.25 ml). One month later, they&#xD;
      are going to receive a second dose of EV71 vaccine and influenza vaccine, simultaneously.&#xD;
      Blood samples are collected before the first vaccination, and one month following the second&#xD;
      vaccination.&#xD;
&#xD;
      378 subjects from the control group A will be only administrated with two doses of EV71&#xD;
      vaccine (0.5 ml) (1 month apart). Blood samples are collected before the first vaccination,&#xD;
      and one month following the second vaccination.&#xD;
&#xD;
      378 subjects from the control group B will be only administrated with two doses of influenza&#xD;
      vaccine (0.25 ml) (1 month apart). Blood samples are collected before the first vaccination,&#xD;
      and one month following the second vaccination.&#xD;
&#xD;
      To evaluate the immunogenicity, we will detect and compare the neutralization antibody&#xD;
      levels, the seroprotection rates, and antibody geometric mean concentrations. The safety of&#xD;
      all groups will be monitored as well.&#xD;
    </textblock>
  </detailed_description>
  <overall_status>Active, not recruiting</overall_status>
  <start_date type="Actual">September 16, 2019</start_date>
  <completion_date type="Anticipated">July 2021</completion_date>
  <primary_completion_date type="Actual">January 6, 2020</primary_completion_date>
  <phase>Phase 4</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Prevention</primary_purpose>
    <masking>Single (Outcomes Assessor)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Seroconversion rate I</measure>
    <time_frame>Baseline (before vaccination) and 1 month after the last dose</time_frame>
    <description>the rate of positive seroconversion against EV71</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Seroconversion rate II</measure>
    <time_frame>Baseline (before vaccination ) and 1 month after the last dose</time_frame>
    <description>the rate of positive seroconversion against Influenza A (H3N2, H1N1) and B Type viruses</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Geometric mean titer (GMT) I</measure>
    <time_frame>Baseline (before vaccination) and 1 month after the last dose</time_frame>
    <description>Measure neutralizing antibody titers against EV71</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Geometric mean titer (GMT) II</measure>
    <time_frame>Baseline (before vaccination) and 1 month after the last dose</time_frame>
    <description>Measure neutralizing antibody titers against Influenza A (H3N2, H1N1) and B Type viruses</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>adverse events following vaccination</measure>
    <time_frame>6 months</time_frame>
    <description>analyse the numbers and rates of participants who experience adverse events following immunization</description>
  </secondary_outcome>
  <number_of_arms>3</number_of_arms>
  <enrollment type="Anticipated">1134</enrollment>
  <condition>Enterovirus Infections</condition>
  <condition>Influenza</condition>
  <arm_group>
    <arm_group_label>experimental group</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>378 subjects from the experimental group will be simultaneously administrated with one dose of EV71 vaccine (0.5 ml) and one dose of influenza vaccine (0.25 ml). One month later, they are going to receive a second dose of EV71 vaccine and influenza vaccine, simultaneously.</description>
  </arm_group>
  <arm_group>
    <arm_group_label>control group A</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
    <description>378 subjects from the control group A will be only administrated with two doses of EV71 vaccine (0.5 ml) (1 month apart).</description>
  </arm_group>
  <arm_group>
    <arm_group_label>control group B</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
    <description>378 subjects from the control group B will be only administrated with two doses of influenza vaccine (0.25 ml) (1 month apart).</description>
  </arm_group>
  <intervention>
    <intervention_type>Biological</intervention_type>
    <intervention_name>EV71 vaccine and influenza vaccine</intervention_name>
    <description>simultaneously administrated with EV71 vaccine and influenza vaccine</description>
    <arm_group_label>experimental group</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Biological</intervention_type>
    <intervention_name>EV71 vaccine</intervention_name>
    <description>administrated with EV71 vaccine only</description>
    <arm_group_label>control group A</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Biological</intervention_type>
    <intervention_name>influenza vaccine</intervention_name>
    <description>administrated with influenza vaccine only</description>
    <arm_group_label>control group B</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:&#xD;
&#xD;
          -  subjects aged from 6-11 months old at the date of recruitment;&#xD;
&#xD;
          -  with informed consent signed by parent(s) or guardians;&#xD;
&#xD;
          -  parent(s) or guardians are able to attend all planned clinical appointments and comply&#xD;
             with all study instructions;&#xD;
&#xD;
          -  subjects not receive any vaccination within 14 days at the date of recruitment;&#xD;
&#xD;
          -  subjects have not been vaccinated with EV71 vaccine, seasonal flu vaccine;&#xD;
&#xD;
          -  subjects with no medical history of EV71 infection;&#xD;
&#xD;
          -  axillary temperature ≤37.0℃&#xD;
&#xD;
        Exclusion Criteria:&#xD;
&#xD;
          -  subject who has a medical history with Hypersensitiveness, eclampsia, epilepsy,&#xD;
             cerebropathia and neurological illness;&#xD;
&#xD;
          -  allergic to any ingredient of vaccine or with allergy history to any vaccine;&#xD;
&#xD;
          -  subjects with immunodeficency or suspected impairment of immunologic function (e.g.&#xD;
             caused by HIV), or subjects are in the process of immunosuppressor therapy(Taking&#xD;
             orally injecting of steroid hormone);&#xD;
&#xD;
          -  administration of immunoglobulins within 30 days prior to this study;&#xD;
&#xD;
          -  acute febrile disease(temperature ≥ 37.0°C) or infectious disease;&#xD;
&#xD;
          -  have a clearly diagnosed history of thrombocytopenia or other coagulopathy,&#xD;
&#xD;
          -  may cause contraindications for subcutaneous injection;&#xD;
&#xD;
          -  any serious chronic illness, acute infectious diseases, or respiratory diseases;&#xD;
&#xD;
          -  severe cardiovascular disease, liver and kidney diseases or diabetes mellitus with&#xD;
             complications;&#xD;
&#xD;
          -  any kind of infectious, purulent, or allergic skin diseases;&#xD;
&#xD;
          -  any other factor that makes the investigator determines the subject is unsuitable for&#xD;
             this study.&#xD;
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>6 Months</minimum_age>
    <maximum_age>11 Months</maximum_age>
    <healthy_volunteers>Accepts Healthy Volunteers</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Hanqing He</last_name>
    <role>Principal Investigator</role>
    <affiliation>Zhejiang Provincial Center for Disease Control and Prevention</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>Zhejiang provincial center for disease control and prevention</name>
      <address>
        <city>Hangzhou</city>
        <state>Zhejiang</state>
        <zip>310051</zip>
        <country>China</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>China</country>
  </location_countries>
  <verification_date>February 2021</verification_date>
  <study_first_submitted>September 15, 2019</study_first_submitted>
  <study_first_submitted_qc>September 16, 2019</study_first_submitted_qc>
  <study_first_posted type="Actual">September 17, 2019</study_first_posted>
  <last_update_submitted>February 24, 2021</last_update_submitted>
  <last_update_submitted_qc>February 24, 2021</last_update_submitted_qc>
  <last_update_posted type="Actual">February 26, 2021</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <keyword>EV71 vaccine</keyword>
  <keyword>influenza vaccine</keyword>
  <keyword>simultaneously administration</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Influenza, Human</mesh_term>
    <mesh_term>Enterovirus Infections</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Vaccines</mesh_term>
  </intervention_browse>
  <patient_data>
    <sharing_ipd>No</sharing_ipd>
  </patient_data>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

